-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$51.508.06% Upside
Recent Analyst Forecasts and Stock Ratings
Kymera Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Kymera Therapeutics, Inc.?
Kymera Therapeutics, Inc. has been rated by research analysts at Oppenheimer, Wolfe Research, H.C. Wainwright, Piper Sandler, Wells Fargo, Morgan Stanley in the past 90 days.